Hims stock is near a buy point of 60.55 in a cup-with-handle base. The IBD 50 growth stock has gained 126% year-to-date.

Hims & Hers Health, Inc. (HIMS) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

After market close Thursday, Hims & Hers disclosed in a regulatory filing that COO Nader Kabbani had vacated his position.

The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...

Many investors have fallen in love with Hims & Hers (HIMS) because weight-loss drugs have been a powerful catalyst for this emerging tele-health company’s initial growth. HIMS kept at weight loss ...

Hims & Hers Health (HIMS) has seen its stock climb steadily, jumping 39% in the past month. This upward trend is catching attention, with investors curious about what is fueling the company’s ongoing ...

Today, Benzinga 's options scanner spotted 32 uncommon options trades for Hims & Hers Health. This isn't normal. The overall ...

Federal health officials are cracking down on telehealth companies’ promotion of unapproved versions of prescription drugs.

Hims & Hers is promoting Chief Commercial Officer Mike Chi to operating chief. Chi will succeed Nader Kabbani as chief operating officer on Nov. 2, the digital healthcare company said. Kabbani plans ...

Hims & Hers Health, Inc. stock may offer more upside amid digital health growth, despite FDA scrutiny and tariff risks. Click ...

The Trump administration has issued its first warnings to online services that offer unofficial versions of popular drugs ...

Financial giants have made a conspicuous bearish move on Hims & Hers Health. Our analysis of options history for Hims & Hers Health (NYSE:HIMS) revealed 13 unusual trades. Delving into the details, we ...